FY2028 Earnings Estimate for CLDX Issued By Leerink Partnrs

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Investment analysts at Leerink Partnrs reduced their FY2028 earnings per share estimates for Celldex Therapeutics in a report released on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now expects that the biopharmaceutical company will earn $0.99 per share for the year, down from their previous estimate of $1.04. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share. Leerink Partnrs also issued estimates for Celldex Therapeutics’ FY2029 earnings at $6.67 EPS.

A number of other equities research analysts have also commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research note on Thursday, December 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Celldex Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $62.25.

Celldex Therapeutics Price Performance

Shares of CLDX stock opened at $23.29 on Thursday. Celldex Therapeutics has a one year low of $22.17 and a one year high of $53.18. The business’s 50 day simple moving average is $25.32 and its 200 day simple moving average is $30.67. The stock has a market capitalization of $1.55 billion, a PE ratio of -9.06 and a beta of 1.60.

Institutional Investors Weigh In On Celldex Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. KBC Group NV lifted its holdings in shares of Celldex Therapeutics by 31.2% in the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 495 shares in the last quarter. AQR Capital Management LLC lifted its stake in shares of Celldex Therapeutics by 23.7% in the second quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company’s stock valued at $291,000 after buying an additional 1,504 shares in the last quarter. Los Angeles Capital Management LLC grew its holdings in shares of Celldex Therapeutics by 128.9% during the fourth quarter. Los Angeles Capital Management LLC now owns 15,421 shares of the biopharmaceutical company’s stock valued at $390,000 after buying an additional 8,683 shares during the last quarter. Handelsbanken Fonder AB increased its position in shares of Celldex Therapeutics by 23.2% during the third quarter. Handelsbanken Fonder AB now owns 13,800 shares of the biopharmaceutical company’s stock worth $469,000 after acquiring an additional 2,600 shares in the last quarter. Finally, Point72 DIFC Ltd raised its holdings in shares of Celldex Therapeutics by 101.7% in the 3rd quarter. Point72 DIFC Ltd now owns 14,114 shares of the biopharmaceutical company’s stock worth $480,000 after acquiring an additional 7,116 shares during the last quarter.

Insider Transactions at Celldex Therapeutics

In other news, CEO Anthony S. Marucci bought 11,500 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The stock was acquired at an average cost of $26.82 per share, with a total value of $308,430.00. Following the transaction, the chief executive officer now directly owns 40,284 shares of the company’s stock, valued at approximately $1,080,416.88. This represents a 39.95 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 3.80% of the company’s stock.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.